Zealand Pharma A/S has appointed Matthew Dallas as its chief financial officer, effective 7 October, to oversee the commercialisation of its peptide-based medicines. Mr Dallas was most recently CFO at Aveo Pharmaceuticals Inc, and prior to that, CFO at CoLucid Pharmaceuticals Inc which was acquired by Eli Lilly and Co in 2017. His earlier career included positions at Genzyme (now part of Sanofi SA) and Kimberly Clark Corp.
Mr Dallas holds a bachelor’s degree in business administration from the University of Tennessee, US.
Zealand Pharma announced the appointment on 28 August 2019.
Copyright 2019 Evernow Publishing Ltd.